Stockwinners Market Radar for December 09, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:16 EST Engaged Capital reports 6.5% stake in Rent-A-Center - The filing allows for activism.

17:13 EST SAIC awarded $349.5M Navy contract modification - SAIC was awarded a $349.5M indefinite-delivery/indefinite-quantity contract for support to execute in-service engineering agent, or ISEA, functions for afloat and ashore tactical networks, or TACNET. Specifically, Naval Information Warfare Center, or NIWC, Pacific requires ISEA support, technical and engineering assistance, design analysis, network information assurance accreditation, installation, integration, sustainment, and life cycle support ISEA functions for afloat and ashore TACNET and command, control, communications, computers, and intelligence systems including the sustainment of fielded systems through end-of-life replacement, system upgrades, follow-on, or interrelated system, distant support, onsite repair, installations, and system analysis to ensure networks are performing within designed specifications and peak capabilities. The contract includes a single five-year ordering period. The period of performance of the base award is from December 9 through December 8, 2027. Work will be annotated at the task order level. Funding will be obligated via task orders. The predominant types of funding anticipated to be obligated on task orders include operations and maintenance; other procurement; research, development, test and evaluation; and shipbuilding and conversion. This contract was competitively procured via Request for Proposal N66001-22-R-0030 which was published on the System for Award management website and the Naval Information Warfare Systems Command E-Commerce Central website. One offer was received and selected for award. NIWC Pacific is the contracting activity.

16:42 EST Nasdaq halts trading in Pingtan Marine Enterprise - The Nasdaq Stock Market announced that trading was halted today in Pingtan Marine Enterprise Ltd. at 09:14:21 A.M. Eastern Time for "additional information requested" from the company at a last sale price of 57c. Trading will remain halted until Pingtan Marine Enterprise Ltd. has fully satisfied Nasdaq's request for additional information.

16:35 EST Gulf Resources notified by government to temporarily close bromine facilities - Gulf Resources announced that it received an oral notification from the government of Shouguang City on December 8, 2022, pursuant to which its all bromine facilities in Shouguang City will be temporarily closed from December 10, 2022 until February 1, 2023 8:00 AM China Time. To comply with such notification, the company expects to temporarily stop production at its bromine facilities in Shouguang City during the aforesaid period. "We believe this seasonal closure ordered by the government is part of governmental action plan to curb air pollution, which becomes worse in the winter, and improve the comprehensive development efficiency of brine resources. The company does not anticipate the closure will have a significant impact on the company's business for the fourth quarter of 2022, for the full year 2022, or for 2023. Further, in 2021-2022, the prior seasonal closure went from December 28, 2021 until February 21, 2022 8:00 AM China Time. There will be fewer days of closure for the 2022-2023 than the year for 2021-2022 ordered by these two government notifications. In general, winter is a slow period for bromine sales. Our customers are closed for Chinese New Year holidays, so they do not place large orders prior to their closure. Further, it is difficult to process crude salt during the coldest months because of low temperatures."

16:20 EST Albany International raises quarterly dividend 19% to 25c from 21c per share - The dividend is payable January 9, 2023, to shareholders of record on December 27, 2022.

16:16 EST Evolve Transition receives NYSE American notice over listing standard - Evolve Transition Infrastructure LP announced that on December 6, 2022, the Partnership received a deficiency letter from NYSE American LLC stating that the Partnership was below compliance with the NYSE American continued listing standards of the NYSE American Company Guide, which requires Evolve to report partners' capital of $2.0 million or more if it has also reported losses from continuing operations and/or net losses in two of its three most recent fiscal years (Section 1003(a)(i)) or to report partners' capital of $4.0 million or more if it has also reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The receipt of the deficiency letter has no immediate impact on the listing of the Partnership's common units, which will continue to trade on NYSE American subject to the Partnership's compliance with other continued listing standards of NYSE American. In accordance with applicable NYSE American procedures, the Partnership must submit a plan by January 5, 2023 advising of actions it has taken or will take to regain compliance with the continued listing standard by June 6, 2024. The Partnership is currently evaluating its available options and intends to develop a plan to be submitted no later than January 5, 2023.

16:12 EST Twilio announces voluntary delisting from Long-Term Stock Exchange - Twilio announced that it has applied to voluntarily delist its Class A common stock from the Long-Term Stock Exchange. Accordingly, it is anticipated that, effective at the close of markets on December 29, 2022, Twilio's shares of Class A common stock will no longer be dual-listed on the LTSE but will continue to trade and be listed on the New York Stock Exchange under the symbol "TWLO." As part of Twilio's commitment to non-GAAP operating profitability beginning in 2023, the company has evaluated discretionary expenses and determined that the costs associated with maintaining a dual listing were no longer justified.

16:08 EST Blue Hat Interactive receives Nasdaq minimum bid price notification - Blue Hat Interactive Entertainment Technology announced that on December 6, 2022, it has received a notification letter from The Nasdaq Stock Market LLC notifying the company that it is not in compliance with the minimum bid price requirement from October 24, 2022 through December 5, 2022, as set forth in Nasdaq Listing Rules 5550(a)(2), which require that the closing bid price for the company's ordinary shares listed on Nasdaq be maintained at a minimum of $1.00 and failure to meet it for 30 consecutive trading days constitutes a compliance deficiency. The notification has no immediate effect on the listing of the company's ordinary shares on Nasdaq.

16:02 EST PolyPid receives noncompliance notification from Nasdaq - PolyPid announced it has received a written notice from Nasdaq Stock indicating that the company is not in compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550, which requires listed securities to maintain a minimum bid price of $1.00 per share. Under Nasdaq Listing Rule 5810, the company has been granted a period of 180 calendar days to regain compliance with the minimum bid price requirement. The notice has no immediate effect on the company's Nasdaq listing or the trading of its ordinary shares, and during the grace period, as may be extended, the company's ordinary shares will continue to trade on Nasdaq under the symbol (PYPD).

15:18 EST BofA CEO, asked about Treasury 'short list' report, says has 'best job in world' - Bank of America CEO Brian Moynihan, asked while being interviewed on CNBC about a report that he is on the White House's short list to replace Treasury Secretary Janet Yellen if she decides to leave her post, replied "I have the best job in the world." When pressed on whether he would consider leaving the private sector for a position in the federal government, Moynihan said: "It has not occurred to me."

14:19 EST UAW says GM Ultium venture workers voted to join union - The UAW announced that Ultium workers voted "overwhelmingly" in favor of joining the UAW by a vote of 710 to 16, with 1 void. Ultium Cells LLC is a joint venture between General Motors and LG Energy Solutions. "Our entire union welcomes our latest members from Ultium. As the auto industry transitions to electric vehicles, new workers entering the auto sector at plants like Ultium are thinking about their value and worth. This vote shows that they want to be a part of maintaining the high standards and wages that UAW members have built in the auto industry," says UAW President Ray Curry. Reference Link

14:01 EST Franklin Resources Canada announces approval of changes for certain ETFs - Franklin Templeton Canada announced that investors have approved the new investment objectives for two equity ETFs and the merger of two fixed income ETFs at special meetings held December 9, 2022. Effective on or around December 21, 2022, Franklin Emerging Markets Multifactor Index ETF and Franklin FTSE Europe ex U.K. Index ETF will have a new index provider, Solactive AG, and adopt new investment objectives and names.

13:06 EST Rio Tinto acquisition of Turquoise Hill receives shareholder support - Rio Tinto (RIO) said it has received the required support from Turquoise Hill Resources Ltd (TRQ) shareholders for its proposed acquisition of the approximately 49% of the issued and outstanding shares of Turquoise Hill that it does not currently own. Given the transaction is being conducted by way of a Canadian plan of arrangement, it remains subject to the final approval of the Supreme Court of Yukon with a hearing scheduled for 14 December. Completion of the acquisition is expected in the days following court approval, after customary closing procedures. Rio Tinto Copper CEO Bold Baatar said: "We welcome the support from minority shareholders, which is a key milestone in our acquisition of TRQ. This transaction will deliver significant benefits for all shareholders, and allow us to progress the Oyu Tolgoi project in partnership with the Government of Mongolia with a simpler and more efficient governance and ownership structure."

13:01 EST Baker Hughes reports U.S. rig count down 4 to 780 rigs

12:26 EST Disney+ Basic not currently available on Roku devices - Disney (DIS) said on its support site that Disney+ Basic, its first-ever ad-supported plan that launched Thursday, is not currently available on Roku (ROKU) devices. This means that viewers are unable to sign up for this plan on Roku devices or stream Disney+ on Roku devices if viewers have this plan or the Disney Bundle Duo Basic or Trio Basic. Streaming of Disney+ Basic (With Ads) is not available on Roku devices or the Microsoft (MSFT) Windows Desktop app. Reference Link

12:10 EST Huntington Ingalls appoints Leo Denault to board of directors - HII (HII) announced that current executive chairman and former CEO of Entergy Corporation (ETR) Leo Denault was elected to the company's board of directors, effective Dec. 5, 2022.

12:00 EST Apple says employees have 'right to speak freely' about workplace conditions - In a report titled "Our Commitment to an Open and Collaborative Workplace", Apple said, "At Apple, our commitment to a safe, inclusive, and respectful work environment is backed by a comprehensive policy that forbids harassment and discrimination. We believe open and honest communication among team members, managers, and leaders helps create a collaborative culture where everyone can contribute, grow, and succeed. Our policies are clear that employees have the right to speak freely about their workplace conditions, including harassment and discrimination, and we offer a range of resources for employees to address questions and report concerns. Our policies extend protections beyond minimum legal requirements, and we continuously review them. In 2018, after evaluating our policies and practices, we made adjustments so that new U.S. employees may choose to opt out of agreements to arbitrate disputes, and harassment and discrimination matters have been excluded from mandatory arbitration for all employees. Starting in January 2022, Apple also voluntarily committed to include California's Silenced No More Act language in separation agreements going forward across the U.S., regardless of where employees work. At Apple, we work every day to create an inclusive, safe, and supportive environment for all our team members. We believe we're a better and more innovative company when people have support and the opportunity to be their best selves." Reference Link

12:00 EST Sunlands Online falls -14.2% - Sunlands Online is down -14.2%, or -$1.05 to $6.34.

12:00 EST Braemar Hotels & Resorts rises 14.5% - Braemar Hotels & Resorts is up 14.5%, or 50c to $3.95.

12:00 EST Huya rises 32.0% - Huya is up 32.0%, or 90c to $3.71.

11:13 EST Phillips 66 announces 2023 capital program of $2B - Phillips 66 announced a 2023 capital program of $2B, including $865M for sustaining capital and $1.1B for growth capital. "Approximately 50% of growth capital supports lower-carbon opportunities. The capital program is consistent with the company's commitment to maintain a $2 billion annual budget through 2024," the company started. "The 2023 capital program reflects our ongoing commitment to capital discipline. Through our Business Transformation, we are capturing $200 million of sustaining capital efficiencies while prioritizing safety and reliability. We are also investing in returns-focused growth opportunities, including enhancing our NGL platform and converting our Rodeo facility to produce lower-carbon renewable fuels. Additionally, the capital program supports our commitment to return $10 billion to $12 billion to shareholders between the second half of 2022 and the end of 2024 through a secure, competitive and growing dividend and share repurchases," added Mark Lashier, President and CEO of Phillips 66.

10:50 EST Elanco announces FDA approval of Bexacat - Elanco Animal Health announced the U.S. Food and Drug Administration approved Bexacat, an orally administered prescription medication to improve glycemic control in cats with diabetes mellitus, expanding Elanco's feline portfolio while addressing an unmet need for this chronic condition in adult cats. Bexacat is anticipated to be available to U.S. veterinarians in the first quarter of 2023.

10:33 EST IBM Canada to open Client Innovation Centre in Fredericton - IBM Canada announced an IBM Client Innovation Centre for Fredericton, with plans to create up to 250 new jobs in New Brunswick. The CIC will have an initial focus on delivering consulting services along with Oracle-based technologies, cloud, machine learning, robotic process automation, the Internet of Things, blockchain and more. IBM is working with the Government of New Brunswick through Opportunities New Brunswick, the lead economic development agency for New Brunswick, to establish the new CIC. Roles in the Fredericton-based centre will include application developers, technical testers, business analysts, customer experience, design consulting, digital transformation and more, all of which are in demand by Canadian businesses. The CIC will assume a portion of the IBM security hub space also located in Fredericton.

10:09 EST Exact Sciences announces initial clinical validation data for POLAR - Exact Sciences shared initial clinical validation data for its breast cancer radiation signature, Profile for the Omission of Local Adjuvant Radiotherapy, at the 2022 San Antonio Breast Cancer Symposium. The meta-analysis of three independent, randomized clinical trials identified which early-stage breast cancer patients benefited from radiotherapy after breast-conserving surgery. The analysis found that patients at low risk for local regional recurrence following breast-conserving surgery did not benefit from radiotherapy. The meta-analysis included 623 patients with lymph node-negative, estrogen receptor-positive, HER2-negative breast cancer who were enrolled in one of three randomized clinical trials, the Swedish SweBCG91RT trial, Scottish Conservation Trial, and Canadian trial from the Princess Margaret Hospital, examining the efficacy of breast-conserving surgery with and without local breast radiation therapy. To validate the POLAR signature as both prognostic and predictive, the investigators analyzed gene expression in breast tumor samples to assign each patient a POLAR score. They then examined the impact of radiation therapy for patients with high and low scores. Among the 479 patients with high POLAR scores, those who did not receive adjuvant radiation therapy after breast-conserving surgery had a 63 percent greater risk of local recurrence compared with those who did receive adjuvant radiation therapy. For the 194 patients with low POLAR scores, there was no significant difference in local recurrence rate between those who received adjuvant radiation therapy and those who did not. After 10 years, five percent of patients who received radiation therapy experienced a local recurrence, compared with seven percent of those who did not receive radiation therapy.

10:01 EST Locafy Ltd trading resumes

10:00 EST Sunlands Online falls -13.4% - Sunlands Online is down -13.4%, or -99c to $6.40.

10:00 EST Braemar Hotels & Resorts rises 12.9% - Braemar Hotels & Resorts is up 12.9%, or 45c to $3.90.

10:00 EST UpHealth rises 83.3% - UpHealth is up 83.3%, or $1.97 to $4.34.

09:47 EST Carvana falls -9.5% - Carvana is down -9.5%, or -47c to $4.49.

09:47 EST Torrid falls -15.6% - Torrid is down -15.6%, or -67c to $3.60.

09:47 EST Korea Electric Power rises 8.4% - Korea Electric Power is up 8.4%, or 62c to $8.03.

09:40 EST Pharvaris NV trading resumes

09:35 EST Pharvaris NV trading halted, volatility trading pause

09:32 EST Sunlands Technology Group - ADR trading halted, volatility trading pause

09:22 EST Motorsport Games enters equity purchase agreement for up to $2M - Motorsport Games announced that the Company has entered into a purchase agreement with an investor for up to $2M, which amount may increase at the Company's option to $10M. Under the terms and conditions of the Agreement, the Company has the right, but not the obligation, to sell to the investor up to $2M of its shares of common stock, which amount may increase at the Company's option to up to $10M in shares, until December 31, 2023, subject to certain limitations. Any shares of common stock that is sold to the investor will occur at a purchase price that is determined in part by prevailing market prices at the time of each sale. The investor has agreed not to cause or engage in any short selling or hedging of the Company's common stock. The Company issued common shares to the investor as consideration for the investor's commitment to purchase the Company's common stock under the Agreement.

09:21 EST Apple, Ericsson sign global patent license agreement - Ericsson (ERIC) and Apple (AAPL) have reached a multi-year, global patent license agreement between the two companies. The agreement includes a cross-license relating to patented cellular standard-essential technologies and grants certain other patent rights. Furthermore, Ericsson and Apple have mutually agreed to strengthen their technology and business collaboration, including in technology, interoperability and standards development. This settlement ends the lawsuits filed by both companies in several countries, including in the United States District Court of the Eastern District of Texas, as well as the complaints filed before the United States International Trade Commission. Ericsson's IPR licensing revenues continue to be affected by several factors, including expired patent license agreements pending renewal, the technology shift from 4G to 5G, and possible currency effects and geopolitical impact going forward. Including effects of the agreement with Apple covering sales from January 15, 2022, and including ongoing IPR business with all other licensees, Ericsson estimates the fourth quarter 2022 IPR licensing revenues will be SEK 5.5 - 6.0 b. Christina Petersson, Chief Intellectual Property Officer at Ericsson says: "We are pleased to settle the litigations with Apple with this agreement, which is of strategic importance to our 5G licensing program. This will allow both companies to continue to focus on bringing the best technology to the global market."

09:09 EST JiuGe, Munich Re deploy behavioral analytic platform for commercial roll-out - Shanghai JiuGe Information Technology and Munich Re have set the stage for extension of their ongoing behavioral research and analytic studies into commercial implementation in the China market. Through a proprietary behavior intelligence system developed by "Sapientus", the analytic innovation development arm of FingerMotion, the partner companies will bring forward their jointly developed model algorithms and analytic insights for productionized applications and wider market adoption. The companies said, "Continuing from our initial collaboration, this subsequent step marks the beginning of a journey towards commercial realization of our joint research and data intelligence, leveraging Munich Re's insurance expertise and industry experience, coupled with Sapientus' proprietary analytic approach and behavioral indicators. Following months of research and calibration of our datasets and models, we are ready to put into practice our behavioral rating services driven by new insights derived from emerging sources of information and advanced analytical techniques for enhancing the predictability of insured behaviors and risk propensities. The analytic system we have built together could catalyze numerous benefits for the industry. We are guided by our commitment in pushing forward a more efficient and intelligent insurance business model through finer delineation of customer profiles and risk groupings, as well as smarter claims and fraud management solutions. Our collaborative exploration to date and progressing undertakings will commercially enable a wide array of value enhancing initiatives and competitive advantages across the chain - improving underwriting excellence, preferred risk selection and new product innovations, just to name a few."

09:05 EST Shift Technologies closes merger with CarLotz - Shift Technologies (SFT) has closed its merger with CarLotz (LOTZ), a leading consignment-to-retail used vehicle marketplace. The combined company will continue to trade on Nasdaq under the ticker SFT. CarLotz shareholders at the effective time of the merger will receive approximately 0.705 shares of Shift common stock for each share of CarLotz common stock, or approximately 84.4 million shares of Shift common stock in the aggregate. In connection with the closing, Jason Krikorian and Manish Patel resigned from the Shift Board of Directors, and Kimberly Sheehy, James Skinner, and Luis Ignacio Solorzano joined the Shift Board of Directors. "On behalf of the Board and entire team at Shift, we'd like to thank Jason and Manish for their endless support, advice, and mentorship over the years," said Jeff Clementz, Shift's CEO. "While we will miss their presence on the Board, we're excited to welcome three new members to help us build a winning, profitable future for Shift." Clementz continued, "As we welcome new members from CarLotz to our team, I'd like to thank Lev, Ozan, and the rest of the CarLotz management team for partnering with us through a successful close. We look forward to combining the best assets from both companies to create a leading destination for used auto retail, allowing consumers to shop and buy cars seamlessly however they prefer, online or in-store."

09:04 EST Clearmind appoints Nicholas Kadysh as special advisor - Clearmind Medicine announced the appointment of seasoned regulatory executive Nicholas Kadysh as special advisor for the development of MEAI as an alcohol substitute. Kadysh, a former executive at Red Bull Canada and Juul Labs Canada, is the founder of PharmAla Biotech, which manufactures MDMA- and MDXX-class molecules for pharmaceutical research, and the Board Chair of Psychedelics Canada, the trade association for the for-profit, legal Canadian psychedelics industry. In parallel to developing its innovative novel psychedelic-derived drug candidate MEAI for treating addictions, Clearmind is also building a parallel track in which MEAI is deployed as an alcohol substitute. The company is currently preforming the safety studies for this.

09:03 EST Altitude Acquisition, medical device maker enter LOI for business combination - Altitude Acquisition announced the signing of a non-binding letter-of-intent for a business combination with a leading global medical device manufacturer. The Target, a leader in its medical device field with a product that is commercially available and approved for use in over 30 countries, seeks additional expansion in the U.S. and globally. Under the terms of the LOI, Altitude and the Target would be become a combined entity, with the Target's existing equity holders rolling 100% of their equity into the combined public company. The proposed transaction values the Target at an enterprise value of $480 million and calls for the combined company to have at least $30M in net cash at the time of closing. Altitude expects to announce additional details regarding the proposed business combination when a definitive merger agreement is executed, which is expected in the first quarter of 2023. Completion of a business combination with the Target is subject to, among other matters, the completion of due diligence, the negotiation of a definitive agreement providing for the transaction, satisfaction of the conditions negotiated therein and approval of the transaction by the board and stockholders of both Altitude and the Target . There can be no assurance that a definitive agreement will be entered into or that the proposed transaction will be consummated on the terms or timeframe currently contemplated, or at all.

08:59 EST Tivic Health, Reliefband Technologies terminate merger agreement - Tivic Health announced that Tivic Health and Reliefband Technologies have, by mutual agreement, terminated the parties' agreement for the acquisition of the Reliefband product line and related assets entered into on October 7. Information regarding the termination is contained in the company's current report on Form 8-K filed with the SEC.

08:45 EST Arcellx trading resumes

08:41 EST Nordic American Tankers provides update on spot contracts - In a letter to investors, Nordic American Tankers said, "Below are the 5 most recent contracts for our suezmax ships, showing the level of the market. All numbers are approximations. Vessel fixed to a major oil trader for a voyage from West Africa to the US East Coast. Time Charter Equivalent of above $70,000/day over more than 40 days. Vessel fixed to a Far East energy company for a voyage from Arabian Gulf to the Far East. The TCE is above $70,000/day over more than 30 days. Vessel fixed to an international oil major for a voyage from South America to UK/Continent. TCE above $80,000/day over more than 40 days. Vessel fixed to an international oil major for a voyage from US Gulf to UK/Continent. TCE above $70,000/day over more than 45 days. Vessel fixed to a Far East major oil company for a voyage from the Arabian Gulf to the Singapore area. TCE is above $50,000/day over more than 30 days. The numbers above give a picture of the current market level.The operating costs for our ships are about $8,000 per day."

08:35 EST Chefs' Warehouse announces pricing of $250M convertible senior notes - The Chefs' Warehouse announced the pricing of $250 million aggregate principal amount of 2.375% Convertible Senior Notes due 2028 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The Company also granted the initial purchasers of the Convertible Notes an option to purchase, for settlement within a period of 13 days from, and including, the date the Convertible Notes are first issued, up to an additional $37.5 million aggregate principal amount of Convertible Notes. The sale of Convertible Notes to the initial purchasers is expected to settle on December 13, 2022, subject to customary closing conditions, and is expected to result in approximately $243.2 million in net proceeds to the Company after deducting the initial purchasers' discounts and commissions and estimated offering expenses payable by the Company. The Convertible Notes will bear interest at a rate of 2.375% per year and will pay interest semiannually in arrears on June 15 and December 15 of each year, beginning on June 15, 2023. The Convertible Notes will mature on December 15, 2028, unless earlier converted, redeemed or repurchased in accordance with their terms. The Company expects to use approximately $159.8 million of the net proceeds from the offering to pay the cash portion of the consideration in the concurrent exchange transactions.The Company intends to use the remainder of the net proceeds from the offering for general corporate purposes.

08:31 EST Rackspace Technology issues update on recent cybersecurity incident - Rackspace Technology issued an update following the recent ransomware incident affecting its Hosted Exchange email business, a managed email solution provided to small and medium businesses. Following the discovery of the incident, Rackspace engaged industry-leading global cybersecurity firm CrowdStrike to help investigate and remediate. Due to swift action on the Company's part in disconnecting its network and following its incident response plans, CrowdStrike has confirmed the incident was quickly contained and limited solely to the Hosted Exchange Email business. "Our Information Security team had strong incident response protocols in place that led to the quick containment of the ransomware attack. We invest time and resources in cybersecurity - we take our processes and procedures very seriously around cyber threats. This is why other parts of our business, and the vast majority of our customers were not affected in any way by the incident and remain secure and fully operational," said Josh Prewitt, Rackspace Chief Product Officer. Rackspace continues to make significant progress in its investigation into the incident. The Company's investigation is also focused on understanding root cause and implementing additional security measures to defend against future cyber threats. Rackspace will share additional updates on these measures with customers as appropriate. "We are a customer-first organization and sincerely apologize for the disruption this incident has caused those customers who utilize our Hosted Exchange email services," Prewitt continued. "We have prioritized getting our customers back on email and have surged our staff and been working around the clock to support them in this transition. We have made significant progress getting customers back on email and will continue to focus our efforts to support customers and get them on email as soon as possible. We are continuing to work on data recovery, which we know is very important to our customers. Rackspace understands the importance of addressing this incident and we've prioritized communication with customers, exploring every potential avenue to reach them, share the information that is known, and most importantly, get them access to email."

08:20 EST Arcellx reports results from CART-ddBCMA Phase 1 expansion trial - Arcellx announced continued robust long-term responses from its CART-ddBCMA Phase 1 expansion trial in patients with relapsed or refractory multiple myeloma, dosing of first patients in its iMMagine-1 Phase 2 clinical trial with pivotal drug product, and the initiation of the Phase 1 clinical trial of ACLX-002 for the treatment of patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. 38 patients were evaluable for efficacy and safety analysis as of the October 31, 2022 cutoff date, based on follow-up of at least one month, following treatment. These evaluable patients comprised the dose escalation cohorts for the first dose level and the second dose level, and a dose expansion cohort at 100. The median dose administered to patients in the first dose level and dose expansion cohorts was 115M CAR+ T cells. All patients evaluable for this analysis have poor prognostic factors with 38 of 38 patients triple-refractory, 26 of 38 penta-refractory, and 22 of 38 with at least one high-risk prognostic factor. All 38 patients had at least 3 prior lines of therapy. The interim CART-ddBCMA Phase 1 clinical results demonstrate deep and durable responses in patients with poor prognostic factors. Based on these data, the recommended Phase 2 dose was selected to be 115 (+/- 10M) CAR+T cells.

08:10 EST Arcellx trading halted, news pending

08:08 EST Triumph Financial announces final results of tender offer - Triumph Financial announced the final results of its modified "Dutch auction" tender offer to purchase up to $100 million of its common stock for cash at a price per share not less than $51.00 and not greater than $58.00, which expired at 12:00 midnight, New York City time, at the end of the day on December 6, 2022. Based on the final count by Equiniti Trust Company, the depositary for the tender offer, a total of 408,615 shares of Triumph's common stock, $0.01 par value per share, were properly tendered at or below the purchase price of $58.00 per share and neither properly withdrawn nor tendered conditionally by any stockholder with conditions that were not met. Triumph has accepted for purchase 408,615 shares of its common stock, $0.01 par value per share, at a price of $58.00 per share, for an aggregate cost of $23,699,670, excluding fees and expenses related to the tender offer. The 408,615 shares that the Company accepted for purchase represent approximately 1.67% of the Company's shares outstanding as of December 5, 2022. As the Company accepted for purchase all of the shares which were properly tendered and not properly withdrawn at a price at or below $58.00, there is no proration factor.

08:07 EST ClearOne, Shure jointly announce settlement of all pending legal disputes - ClearOne and Shure jointly announce that they have reached a global settlement of all pending legal disputes. In order to avoid the expense, burden, and uncertainty associated with litigation and to resolve their pending cases against one another, the companies entered into a confidential settlement agreement. The companies have agreed to file dismissals with prejudice in all pending cases to fully and finally resolve their disputes. Both parties have agreed to release the other party from all claims and to cross-license all patent rights involved with the cases, such that each party will be free to sell their products without restrictions going forward. The companies have also agreed to cross-license certain additional patent rights and have made covenants not to sue. Certain terms of the agreement between the parties are conditional on court action and/or approval, which the parties will promptly seek. Neither company has admitted any wrongdoing or liability as a condition of settlement.

08:06 EST HTG Molecular announces KOL webinar on RNA profiling - HTG Molecular Diagnostics announced it will host its next HTG Therapeutics key opinion leader webinar: "The Role of RNA Profiling in Drug Discovery and Analysis", on Tuesday, December 13, 2022 at 11:00 am Eastern Standard Time. This latest webinar features a presentation from KOL, Dr. Robert Spitale, PhD, from the University of California - Irvine, discussing the use of RNA profiling in the drug discovery process to better uncover mechanism of action and refine the drug screening processes. Additionally, the HTG Therapeutics team will present results from the application of its transcriptome-informed drug discovery process. Specifically, differential regulation of the ferroptosis pathway by structurally similar compounds that target mTOR will be offered as an example of how RNA profiling can aid in understanding post-target engagement consequences and expand our understanding of the biological implications of compound treatment.

08:05 EST Adamas One announces pricing of initial public offering - Adamas One announced the pricing of its underwritten initial public offering of 2,450,000 shares of common stock at an initial public offering price of $4.50 per share for gross proceeds of $11,025,000, before underwriting discounts and commissions and estimated offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to 367,000 additional shares of common stock at the offering price, less the underwriting discount. The shares are expected to begin trading on The Nasdaq Capital Market on December 9, 2022, under the ticker symbol "JEWL." The offering is expected to close on December 13, 2022, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds of this offering primarily for general corporate purposes, including working capital, R&D, operating expenses which may include debt repayment and capital expenditures. Alexander Capital, LP is acting as sole book-running manager for the offering. Greenberg Traurig LLP and Lucosky Brookman LLP served as co-counsel to Adamas. Carmel, Milazzo & Feil LLP served as counsel to the underwriters.

08:04 EST Bionano Genomics announces publication of study evaluating OGM for AML samples - Bionano Genomics announced the publication of a multi-institutional peer-reviewed study initiated by the Cancer Genomics Consortium evaluating the performance of optical genome mapping, OGM, for detection of cytogenetic abnormalities in acute myeloid leukemia, AML, samples. OGM identified structural variants and copy number variants with 100% concordance to traditional cytogenetic methods, added important pathogenic findings in 13% of findings, and uncovered additional genomic events in 12% of samples that may change risk stratification and alter recommended clinical care, including access to clinical trials. In the study published in Blood Advances, researchers used OGM to evaluate its performance in the detection of cytogenetic abnormalities in 100 AML samples that had previously been analyzed using methods including karyotyping, fluorescence in situ hybridization and chromosomal microarray analysis. Key findings were: In five subjects, analysis by OGM resulted in a change in risk stratification score compared to the scores determined by KT; In eight subjects, OGM identified additional genomic events that would have rendered those subjects eligible to participate in research studies evaluating the effectiveness of experimental treatments; In three of the subjects that would be eligible to participate in research studies evaluating the effectiveness of experimental treatments, OGM also showed that potential adverse risks would be independent of TP53, which may allow for them to be safely enrolled in multiple trials with known TP53-related adverse effects. Overall, the research study supports the view that OGM analysis may be useful to assemble a more accurate and complete karyotype by refining cytogenetic breakpoints, resolving unknown cytogenomic elements and detecting additional significant variants. "We are excited to see the findings from this study, which was conducted by a multi-site consortium led by renowned pathologists who, through their memberships in various medical societies, are responsible for defining standards of care and testing throughout pathology. We are gratified to see the authors' recommendation of OGM as a methodology with the potential to become standard-of-care for cytogenomic evaluation of AML samples," commented Erik Holmlin, PhD, president and chief executive officer of Bionano Genomics.

07:39 EST Erasca announces pricing of underwritten offering of common stock - Erasca announced the pricing of an underwritten offering of 15,384,616 shares of its common stock at a price of $6.50 per share. All of the shares to be sold in the offering are to be sold by Erasca. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $100M. The offering is expected to close on December 13, 2022, subject to the satisfaction of customary closing conditions. Erasca intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities, to fund the research and development of its product candidates and other development programs and for working capital and other general corporate purposes. J.P. Morgan and Goldman Sachs & Co. LLC are acting as joint book-running managers for the offering.

07:35 EST Laurentian Bank raises quarterly dividend to C$0.46 per share - At its meeting held on December 8, 2022, the Board of Directors of Laurentian Bank of Canada has approved an increase of C$0.01 on its common shares and declared a regular quarterly dividend of C$0.46 per share on the common shares' payable on February 1, 2023 to the holders of record at the close of business on January 3, 2023.

07:34 EST Irwin Naturals completes acquisition of assets of Clare Clinic - Irwin Naturals completed the acquisition of the assets of Clare Clinic, Inc., d/b/a Florida Mind Health Center. The Company entered into an acquisition agreement dated October 30, 2022 with Clare Clinic, which serves clients out of three healthcare clinics in located in Gainesville, Tallahassee and Panama City, Florida. Klee Irwin, CEO of Irwin Naturals, said "Our roll-up is quickly gathering momentum. This is the eighth ketamine clinic we are adding to our growing portfolio in Florida and is part of our 17 clinics which we have either acquired or have a definitive agreement to acquire in the near future, in over ten states. Our mission is to make this amazingly effective treatment available and accessible throughout the country and beyond. We continue to add to our bottom line through these highly accretive transactions as we focus on acquiring profitable operations." Transaction terms: As consideration for the asset purchase, Irwin Naturals will provide sellers cash payments as well as 1,500,000 subordinate voting shares upon closing. Furthermore, the transaction includes an additional contingent consideration based on future milestones related to operational and profitability targets to be satisfied in shares.

07:32 EST Chart Industries announces pricing of upsized public offerings - Chart Industries announced that it has priced its previously announced concurrent offerings of 5,923,670 shares of common stock, par value $0.01 per share, at a public offering price of $118.17 per share and 7,000,000 depositary shares, each representing a 1/20th interest in a share of Series B Mandatory Convertible Preferred Stock, par value $0.01 per share, at a public offering price of $50 per share, each in a separate underwritten registered public offering. In addition, Chart has granted the underwriters in each respective offering a 30-day option to purchase up to an additional 888,550 shares of Common Stock and up to an additional 1,050,000 Depositary Shares, in each case at the public offering price per share. The net proceeds from the Offerings of Common Stock and Depositary Shares will be approximately $675.5 million and $337.8 million, respectively, in each case after deducting the applicable underwriting discount and before estimated offering expenses payable by Chart. Chart intends to use the proceeds from the Offerings to fund in part the previously announced acquisition of Howden from affiliates of KPS Capital Partners, by reducing the amount of Series A Cumulative Participating Convertible Preferred Stock to be issued to Granite Holdings I B.V., a Dutch private limited liability company, under the equity purchase agreement in connection with the Acquisition.

07:16 EST Just Energy announces delisting, trading halt dates - Just Energy Group announces that, effective at the close of business on Thursday, December 15, 2022, its common shares will be delisted from trading on the NEX board of the TSX Venture Exchange for failure to maintain exchange requirements due to the anticipated closing of the Transaction. As previously announced by the Company on December 1, 2022, trading in the common shares will be halted to facilitate the delisting of the common shares. This halt will become effective at the close of trading on Monday, December 12, 2022 and will remain in effect until delisting is completed. Delisting is occurring in connection with the anticipated closing of the previously announced transactions provided for under the transaction agreement entered into on August 4, 2022, as amended, supplemented or otherwise modified from time to time, among Just Energy and the lenders under the Company's debtor-in-possession financing facility, one of their affiliates and the holder of certain assigned secured claims. Closing of the Transaction is currently expected to occur on December 16, 2022, subject to the satisfaction or waiver of the remaining conditions to closing. As previously announced by the Company, in connection with the completion of the Transaction, the Company: has applied for an order from Canadian securities administrators that it will cease to be a reporting issuer under Canadian securities laws immediately prior to the effective date of the Transaction; and (ii) will file on the date of the completion of the Transaction to suspend its reporting obligations under U.S. securities laws. The Company also expects that its common shares will cease trading from the OTC Pink Sheets in connection with completion of the Transaction. In connection with the Transaction, all common shares trading on the NEX and the OTC Pink Sheets will be cancelled.

07:07 EST ObsEva to increase issued share capital by creating additional treasury shares - ObsEva announced that its board of directors approved on December 8, 2022 an increase of its share capital through the issuance of 20,000,000 newly registered shares at an issue price of 1/13 of a Swiss Franc each. The 20,000,000 new shares, to be issued out of the company's authorized capital, will be fully subscribed for by ObsEva USA Inc., its 100% wholly owned subsidiary, and listed on the SIX Swiss Exchange on or around December 12, 2022. The transaction has been decided to provide the group with additional treasury shares that can be used in the future to raise funds in an efficient manner, as well as for the equity plans of the company and its subsidiaries.

07:06 EST Avista posts updated Corporate Responsibility report - Avista published its latest Corporate Responsibility report and other environmental, social and governance information on its corporate website, avistacorp.com. The content reports on Avista's operations and includes commitments in four areas: environment, people, customers and communities, and ethical governance. The latest updates include Avista's aspirational goals for workplace Equity, Inclusion and Diversity, an aspirational goal related to Supplier Diversity, and the publication of Avista's current Equal Employment Opportunity 2021 Employer Information Report EEO-1 Consolidated Report. The website also provides links to Avista's continued reporting on a series of key industry ESG disclosures and metrics that include new reports adhering to the Sustainability Accounting Standards Board, the Edison Electric Institute and the American Gas Association ESG and sustainability reporting frameworks.

07:05 EST Better World Acquisition, Heritage Distilling enter business combination deal - Better World Acquisition announced it has entered into a Business Combination Agreement with Heritage Distilling Holding Company. The parent company following the consummation of the transaction, Heritage Distilling Group, Inc., will be a new Delaware holding company that will be led by Justin Stiefel, Co-Founder and Chief Executive Officer of Heritage. Pubco's common stock is expected to be listed on the Nasdaq Capital Market following the consummation of the transaction under the ticker symbol "CASK". Better World said, "For the past nine years, Heritage has been the most awarded craft distillery in North America by the American Distilling Institute, and has been recognized for its innovative brand family of premium whiskies, gins, vodkas, rums and ready-to-drink cocktails. As one of the largest independent craft distilleries on the West Coast, Heritage aims to become the leading national craft spirits company. Working collectively with Native American tribes across the country, Heritage is focused on creating a national craft spirits network, with the goal of providing economic benefits to tribes across the country. In collaboration with the Chehalis tribe, Mr. Stiefel successfully worked to overturn a 184-year-old Federal law banning distilling spirits on tribal lands, positioning Heritage to advance its unique operating model. As a result of the business combination, Heritage expects to become one of the only publicly-traded, pure play craft distilleries. The proposed transaction combines Heritage's brands with Better World's consumer products and beverage expertise. Better World brings marketing, finance and capital markets experience that the parties believe will accelerate the growth of Heritage's business." Following the closing of the transaction, and assuming no redemptions by Better World stockholders in connection with the stockholder vote to approve the transaction, it is anticipated the Combined Company will have approximately $44M in cash, prior to the payment of the parties' expenses related to the business combination. Pursuant to the Agreement, each of Heritage and Better World will merge with newly-formed subsidiaries of Pubco, which itself is a newly-formed subsidiary of Better World. As a result of such mergers, Heritage stockholders will receive new shares of Pubco and Better World security holders will exchange their securities of Better World for securities of Pubco. The shares of Pubco common stock to be issued to the Heritage equity holders will have an aggregate value equal to $77.5M, subject to adjustment for certain indebtedness of Heritage as determined in accordance with the Agreement, with each share of Pubco common stock valued at $10.00 per share. Cash proceeds released from Better World's trust account, which currently has approximately $44M in cash, after any stockholder redemptions and payment of transaction expenses and other Better World liabilities, will remain with the combined company. Heritage and Better World are contributing into a CVR escrow account an aggregate of the equivalent of 4,000,000 shares of Pubco common stock and RSUs that will settle into shares of Pubco common stock. The CVRs will provide Better World's public stockholders who do not redeem their shares in connection with the transaction with downside protection. The transaction implies a Pubco pro forma enterprise value of $122.2M immediately after closing of the business combination assuming no redemptions by Better World stockholders and a redemption price of $10.52 per share. As merger consideration, each Better World public stockholder who participates in the business combination will receive: One share of Pubco common stock. One CVR, which provides the holder with a 10% per annum preferred simple return including downside protection ranging from approximately $4.00 to $6.00 per share during the 18-month period following the closing, which may be extended by six months at the option of Better World's sponsor. As merger consideration, each Heritage stockholder who participates in the business combination will receive: Approximately 4.15 shares of Pubco common stock for each share of Heritage common stock held by a stockholder based on Heritage's current capitalization and net debt adjustments. In addition, Heritage stockholders have the contingent right to receive up to 3,000,000 earnout shares from Pubco as additional consideration if the applicable earnout milestones as set forth in the Agreement are achieved by Pubco. Pubco also will assume certain convertible notes, warrants and RSUs issued by Heritage. Assuming no redemptions by Better World's public stockholders, it is estimated that the current security holders of Heritage will own approximately 47% of the issued and outstanding shares in the Combined Company at closing of the transaction. The transaction has been unanimously approved by the boards of directors of both Better World and Heritage. Completion of the transaction is subject to approval by equity holders of each company and certain other conditions specified in the Agreement. The transaction is currently expected to close in the second quarter of 2023.

07:01 EST Palantir, Crisis24 announce new partnership - Palantir Technologies announced a strategic partnership with integrated risk management firm Crisis24, a GardaWorld company, to transform security and risk management with the power of AI. This multi-million dollar long-term strategic partnership will help to reshape security and risk management by leveraging critical information to provide clients with innovative solutions, data-driven insights for results-oriented decision-making that meet their everyday challenges. In a dynamic and interconnected world, effective risk mitigation relies on being able to bring together and comprehend data about global events. Leveraging Crisis24's unparalleled expertise and depth of knowledge in crisis management and intelligence, Palantir's Foundry operating system will enable users to identify critical trends and provide comprehensive analysis of emerging risks around the world as well as develop new offerings for the public and private sectors.

06:47 EST Pfizer, BioNTech get FDA FTD for mRNA-based combination vaccine candidate - Pfizer (PFE) and BioNTech (BNTX) announced the companies have received Fast Track Designation from the U.S. FDA for their mRNA-based combination vaccine candidate for influenza and COVID-19, which aims to help prevent two respiratory diseases with a single injection. The vaccine candidate is based on BioNTech's proprietary mRNA platform technology and contains mRNA strands encoding the wild-type spike protein of SARS-CoV-2 and the spike protein of the Omicron sublineages BA.4/BA.5, as well as mRNA strands encoding the hemagglutinin of four different influenza strains, recommended for the Northern Hemisphere 2022/23 by the World Health Organization.

06:40 EST Crescent Point Energy increases quarterly dividend 25% to 10c per share - Given the company's operational results in 2022, its continued success in improving its financial position and the additional excess cash flow it expects to generate from the assets, the board of directors has approved and declared a 25% increase to the quarterly base dividend to 10c per share, or 40c per share annually, up from 32c per share previously. This increased base dividend is payable on April 3, 2023 to shareholders of record at the close of business on March 15, 2023. Crescent Point's 2023 annual average production guidance is now 138,000 to 142,000 boe/d, an increase of 4,000 boe/d, with development capital expenditures unchanged at $1B to $1.1B. The company now expects to generate approximately $1.25B of excess cash flow at US$80/bbl WTI. This budget, including the base dividend, is fully funded at US$50/bbl WTI. Crescent Point continues to return 50% of its discretionary excess cash flow to its shareholders, in addition to its base dividend. Under this framework, the company expects to return over $700M directly to shareholders in 2023, based on current guidance at $80/bbl WTI. These returns are further supplemented with per-share growth and debt reduction. Crescent Point remains active on its normal course issuer bid and has repurchased over 6.2M shares during fourth quarter 2022 to-date for approximately $65M.

06:33 EST AstraZeneca's Dato-DXd shows 'durable efficacy' in HER2-low patients - Last night, the company announced: "Initial results from the TROPION-PanTumor01 Phase I trial of datopotamab deruxtecan, Dato-DXd, showed encouraging and durable efficacy in patients with heavily pretreated hormone receptor (HR)-positive, HER2-low or HER2-negative unresectable or metastatic breast cancer. Safety results were consistent with previous trials of datopotamab deruxtecan. Results were presented today at the 2022 San Antonio Breast Cancer Symposium. Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody drug conjugate being jointly developed by Daiichi Sankyo and AstraZeneca. In this cohort of TROPION-PanTumor01 (n=41), datopotamab deruxtecan demonstrated an objective response rate of 27% as assessed by blinded independent central review. All responses were partial and 56% of patients achieved stable disease. The disease control rate (DCR) was 85% and median progression-free survival was 8.3 months. With median follow-up of 13.7 months, the median duration of response and the median overall survival (OS) had not been reached with 59% of patients alive for more than one year." Reference Link

06:04 EST TE Connectivity increases quarterly dividend to 59c per share - TE Connectivity announced that its board of directors approved a recommendation to increase the company's quarterly dividend from 56c to 59c per share, for the four fiscal quarters starting in April 2023, the beginning of the third fiscal quarter. The recommendation would raise the company's dividend from the annual rate of $2.24 per share to $2.36 per share, and will be presented for shareholder approval at the company's annual general meeting of shareholders on March 15, 2023.

05:42 EST FCA fines Santander UK GBP 107.7M for repeated anti-money laundering failures - The U.K.'s FCA has fined Santander UK Plc GBP 107,793,300 after it found serious and persistent gaps in its anti-money laundering controls, affecting its Business Banking customers. Between 31 December 2012 and 18 October 2017, Santander failed to properly oversee and manage its AML systems, which significantly impacted the account oversight of more than 560,000 business customers, the FCA said in a statement. Santander had ineffective systems to adequately verify the information provided by customers about the business they would be doing. The firm also failed to properly monitor the money customers had told them would be going through their accounts compared with what actually was being deposited. Mark Steward, Executive Director of Enforcement and Market Oversight at the FCA, said: "Santander's poor management of their anti-money laundering systems and their inadequate attempts to address the problems created a prolonged and severe risk of money laundering and financial crime." Reference Link

05:17 EST ASE Technology reports November revenue $1.89B vs. $2.18B last year - Reports November ATM revenues $1.03B vs. $1.1B last year.